Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07169279 · ClinicalTrials.gov registry record · Phase 2
Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)
A Phase 2 study of Achondroplasia, sponsored by QED Therapeutics, a BridgeBio company.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 77
- Enrollment target
- 13
- Study locations
NCT07169279: Recruiting Phase 2 study of Achondroplasia, sponsored by QED Therapeutics, a BridgeBio company.
NCT07169279 is a Phase 2 study of Achondroplasia that is actively recruiting participants, run by QED Therapeutics, a BridgeBio company. The registered enrollment target is 77 participants, below the 142-participant average among 9 other Achondroplasia trials with a reported enrollment target (46% lower). The trial reports 13 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07169279, a Phase 2 study of Achondroplasia, is actively recruiting participants, sponsored by QED Therapeutics, a BridgeBio company.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 77 participants
- Enrollment target
- 13
- Study locations
Study Summary
This is a Phase 2, multicenter, randomized, placebo-controlled study to evaluate the safety and efficacy of infigratinib in participants \< 3 years old with ACH. The purposes of the SAD and Phase 2 portions are to identify and confirm the dose of infigratinib to be used in the Phase 2b portion, based on safety and PK. The purpose of the Phase 2b, placebo-controlled portion is to evaluate the safety and efficacy of infigratinib in children \< 3 years old with ACH at the selected dose.
Conditions Studied
Interventions
- DRUG Infigratinib is provided as a single dose of minitablets for oral administration
- DRUG Infigratinib is provided as sprinkle capsules for daily oral administration
- DRUG Infigratinib or placebo comparator is provided as sprinkle capsules for daily oral administration
Study Locations (13)
Other
- Paediatric Clinical Research Unit at Oslo University Hospital - Oslo
- KK Women's and Children's Hospital - Singapore
- Unidad de Cirugia Artroscopica (UCA) - Vitoria-Gasteiz
- NHS Greater Glasgow and Clyde - Glasgow
- Guy's and Saint Thomas' NHS Foundation Trust - London
- Manchester University NHS Foundation Trust - Manchester
- Sheffield Children's NHS Foundation Trust - Sheffield
California
- UCSF Benioff Children's Hospital - Oakland
Maryland
- Johns Hopkins University - Baltimore
Wisconsin
- University of Wisconsin Madison - Waisman Center Bone Dysplasia Clinic - Madison
Victoria
- Murdoch Children's Research Institute - Parkville
Ontario
- Children's Hospital of Eastern Ontario Research Institute - Ottawa
Quebec
- Université de Montréal - Centre Hospitalier Universitaire Sainte-Justine - Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2025-11-19 |
| Est. Completion | 2032-03 |
| Phase | Phase 2 |
What NCT07169279 shows while recruiting
NCT07169279 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 77 participants, a relatively small participant target, below the 142-participant average among 9 other Achondroplasia trials with a reported enrollment target (46% lower).
The record links to 1 condition, with Achondroplasia appearing as the primary indexed condition, and to 3 interventions - of which Infigratinib is provided as a single dose of minitablets for oral administration is the first listed.
NCT07169279 lists 13 locations in 7 states (Other, California, Maryland).
Frequently Asked Questions
What is clinical trial NCT07169279 about?
NCT07169279 is a clinical study titled "Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)". This is a Phase 2, multicenter, randomized, placebo-controlled study to evaluate the safety and efficacy of infigratinib in participants \< 3 years old with ACH. The purposes of the SAD and Phase 2 portions are to identify and confirm the dose of infigratinib to be used in the Phase 2b portion, base...
What is the current status of trial NCT07169279?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 77 participants. The study started on 2025-11-19. Estimated completion is 2032-03.
What conditions does trial NCT07169279 study?
This clinical trial studies the following conditions: Achondroplasia.
What interventions are being tested in trial NCT07169279?
The interventions under investigation include: Infigratinib is provided as a single dose of minitablets for oral administration (DRUG), Infigratinib is provided as sprinkle capsules for daily oral administration (DRUG), Infigratinib or placebo comparator is provided as sprinkle capsules for daily oral administration (DRUG).
Who is sponsoring clinical trial NCT07169279?
This trial is sponsored by QED Therapeutics, a BridgeBio company, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07169279 being conducted?
This trial has 13 study locations across California, Maryland, Wisconsin, Victoria, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Achondroplasia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07169279's enrollment target sits among peer trials
77 7th of 9 higher than 3 of 9 other Achondroplasia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Achondroplasia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of TYRA-300 in Children With Achondroplasia: BEACH301
RECRUITING · Phase 2
-
A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With Achondroplasia
RECRUITING · Phase 2
-
An Extension Study to Evaluate Safety and Efficacy of BMN 111 in Children With Achondroplasia
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Evaluate Long-Term Safety, Tolerability, & Efficacy of BMN 111 in Children With Achondroplasia (ACH)
ACTIVE NOT RECRUITING · Phase 2
-
VIrtual STudy in Achondroplasia for the US (VISTA)
RECRUITING
-
Prospective Clinical Assessment Study in Children With Achondroplasia (ACH)
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02127398 · 77 participants · Phase 2
Stool Transplants to Treat Refractory Clostridium Difficile Colitis
- NCT04159103 · 77 participants · Phase 1
Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia
- NCT04683003 · 77 participants · Phase 3
A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura
- NCT05004116 · 77 participants · Phase 1
A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI